不同剂量瑞舒伐他汀对急性冠脉综合征患者血清sOX40L、MMP-9的影响  

Effects of Different Doses of Rosuvastatin on Serum Levels of sOX40L and MMP-9 in Patients with Acute Coronary Syndrome

作　　者：王林军[1] 

机构地区：[1]中医药大学附属连云港市中医院心内科,南京222002

出　　处：《天津医药》2014年第9期937-939,共3页Tianjin Medical Journal

摘　　要：目的探讨不同剂量瑞舒伐他汀对急性冠脉综合征(ACS)患者血清可溶性OX40配体(sOX40L)、基质金属蛋白酶9(MMP-9)的影响。方法选择ACS患者60例,健康对照组20例。随机将ACS患者分为20 mg瑞舒伐他汀治疗组(20 mg组)30例和10 mg瑞舒伐他汀治疗组(10 mg组)30例,比较治疗前后各组间血清sOX40L、MMP-9的水平变化。结果治疗前2个治疗组血清sOX40L、MMP-9水平高于对照组(P<0.01)。瑞舒伐他汀治疗2周后,2个治疗组患者血清sOX40L、MMP-9水平均较治疗前明显降低(P<0.01),其中20 mg组较10 mg组降低更为明显(P<0.05),但2组仍高于对照组(P<0.01)。结论 ACS患者早期使用较大剂量瑞舒伐他汀可明显减少冠状动脉粥样斑块基质成分的降解和炎症反应,从而起到稳定动脉粥样硬化斑块,改善ACS患者预后的作用。Objective To explore effects of different doses of rosuvastatin on serum soluble OX40 ligand （sOX40L）, matrix metalloproteinase-9 （MMP-9） in patients with acute coronary syndrome （ACS）. Methods Sixty patients with ACS were evenly divided into 20 mg rosuvastatin treatment group （20 mg group） and 10 mg rosuvastatin treatment group （10 mg group）. Twenty healthy volunteers were randomly assigned to control group. The serum levels of sOX40L and MMP-9 were measured and analyzed before and after treatment in three groups. Results The levels of sOX40L and MMP-9 before treat-ment were significantly higher in two treatment groups than those in control group （P〈0.01）. After two-week treatment with rosuvastatin, serum levels of sOX40L and MMP-9 decreased significantly in two treatment groups compared with those of pre-treatment （P＆lt;0.01）. Moreover, the levels of sOX40L and MMP-9 were significantly lower in 20 mg group than those in 10 mg group after two-week treatment with rosuvastatin （P〈0.05）. But the levels of sOX40L and MMP-9 were still higher than control group （P〈0.01）. Conclusion Larger doses of rosuvastatin may decrease the degradation of extraceller matrix of coronary atherosclerotic plaque and inflammatory reaction, stabilize coronary atherosclerotic vulnerable plaque, and play an important role in improving prognosis in patients with ACS.

关 键 词：瑞舒伐他汀 冠状动脉疾病 基质金属蛋白酶9 可溶性OX40配体 

分 类 号：R543.3[医药卫生—心血管疾病]